Oryzon Genomics, S.A.

Oryzon develops experimental medicines that change how cells regulate gene activity, with clinical programmes in blood cancers and psychiatric and neurological conditions. Its treatments are still being tested and have not been approved for sale.

Log in to follow
ORY · BME

Overview

Summary

Founded in Barcelona in 2000, Oryzon built its drug-development work around epigenetics: the controls that influence which genes a cell uses. Its two main clinical candidates are iadademstat, being tested mainly in blood cancers, and vafidemstat, being studied in brain-related conditions. Both target the LSD1 enzyme. Oryzon funds trials and seeks regulatory progress or partnerships; it does not yet have a business selling approved medicines.

Latest results

Jan–Sep 2026

Revenue
EUR 0.0 millionUnchanged
Operating profit
-EUR 4.6 millionLoss widened
Cash held
EUR 19.1 million
Financial debt
EUR 9.5 million

Latest financial publication

Nov 10, 2026 · Issuer publication

9M 2026 financial results

Search companies & research

Search companies & research